Eli Lillys Zepbound set to eclipse Wegovy in U.S. obesity drug market Eli Lillys new obesity drug poised to challenge ...

Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory decisions.

Health authorities in Victoria, Australia's second-most populous state, on Tuesday issued a high-risk warning after ...

The market is obsessed with risky options, but disciplined investors know slow and steady wins. Check out three stock picks ...

Ozempic has become a popular wonder drug among many Hollywood celebrities, who turned to the diabetes medication to lose ...

FDA has ordered specialty pharmacies and online companies to phase out knockoff versions of Eli Lilly's blockbuster drugs ...

Stocks are wavering in the early going on Wall Street at the start of a holiday-shortened week. The S&P 500 edged up 0.2% in ...

GLP-1 receptor agonists and dual agonists – such as Ozempic, Wegovy, Mounjaro and Zepbound – are typically used as weekly injections. The GLP-1 receptor agonists work by mimicking the GLP-1 hormone in ...

The FDA has approved Zepbound, a popular weight loss drug, for the treatment of moderate-to-severe obstructive sleep apnea. According to drugmaker Eli Lilly, it’s the first and only FDA ...

The weight loss drug Zepbound has become the first prescription medication approved to treat obstructive sleep apnea. The Food and Drug Administration on Friday authorized the use of Zepbound ...

Dec. 21 (UPI) --Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for treating moderate to severe obstructive sleep apnea.